Addendum to Letter to the Editor

Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1

Pramod K. Mistry, Manisha Balwani, Hagit N. Baris, Hadhami Ben Turkia, T. Andrew Burrow, Joel Charrow, Gerald F. Cox, Sumita Danda, Marta Dragosky, Guillermo Drelichman, Amal El-Beshlawy, Cristina Fraga, Selena Freisens, Sebastiaan Gaemers, Evgueniy Hadjiev, Priya S. Kishnani, Elena Lukina, Pierre Maison-Blanche, Ana Maria Martins, Gregory Pastores & 6 others Milan Petakov, M. Judith Peterschmitt, Hanna Rosenbaum, Barry Rosenbloom, Lisa H. Underhill, Timothy M. Cox*

*Corresponding author for this work

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)101-102
Number of pages2
JournalBlood Cells, Molecules, and Diseases
Volume77
DOIs
StatePublished - Jul 1 2019

Fingerprint

Gaucher Disease
Safety
Therapeutics
eliglustat

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Cite this

Mistry, Pramod K. ; Balwani, Manisha ; Baris, Hagit N. ; Turkia, Hadhami Ben ; Burrow, T. Andrew ; Charrow, Joel ; Cox, Gerald F. ; Danda, Sumita ; Dragosky, Marta ; Drelichman, Guillermo ; El-Beshlawy, Amal ; Fraga, Cristina ; Freisens, Selena ; Gaemers, Sebastiaan ; Hadjiev, Evgueniy ; Kishnani, Priya S. ; Lukina, Elena ; Maison-Blanche, Pierre ; Martins, Ana Maria ; Pastores, Gregory ; Petakov, Milan ; Peterschmitt, M. Judith ; Rosenbaum, Hanna ; Rosenbloom, Barry ; Underhill, Lisa H. ; Cox, Timothy M. / Addendum to Letter to the Editor : Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. In: Blood Cells, Molecules, and Diseases. 2019 ; Vol. 77. pp. 101-102.
@article{9b962eea0b1547e083fa16b07021fc98,
title = "Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1",
author = "Mistry, {Pramod K.} and Manisha Balwani and Baris, {Hagit N.} and Turkia, {Hadhami Ben} and Burrow, {T. Andrew} and Joel Charrow and Cox, {Gerald F.} and Sumita Danda and Marta Dragosky and Guillermo Drelichman and Amal El-Beshlawy and Cristina Fraga and Selena Freisens and Sebastiaan Gaemers and Evgueniy Hadjiev and Kishnani, {Priya S.} and Elena Lukina and Pierre Maison-Blanche and Martins, {Ana Maria} and Gregory Pastores and Milan Petakov and Peterschmitt, {M. Judith} and Hanna Rosenbaum and Barry Rosenbloom and Underhill, {Lisa H.} and Cox, {Timothy M.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.bcmd.2019.04.003",
language = "English (US)",
volume = "77",
pages = "101--102",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",

}

Mistry, PK, Balwani, M, Baris, HN, Turkia, HB, Burrow, TA, Charrow, J, Cox, GF, Danda, S, Dragosky, M, Drelichman, G, El-Beshlawy, A, Fraga, C, Freisens, S, Gaemers, S, Hadjiev, E, Kishnani, PS, Lukina, E, Maison-Blanche, P, Martins, AM, Pastores, G, Petakov, M, Peterschmitt, MJ, Rosenbaum, H, Rosenbloom, B, Underhill, LH & Cox, TM 2019, 'Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1', Blood Cells, Molecules, and Diseases, vol. 77, pp. 101-102. https://doi.org/10.1016/j.bcmd.2019.04.003

Addendum to Letter to the Editor : Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. / Mistry, Pramod K.; Balwani, Manisha; Baris, Hagit N.; Turkia, Hadhami Ben; Burrow, T. Andrew; Charrow, Joel; Cox, Gerald F.; Danda, Sumita; Dragosky, Marta; Drelichman, Guillermo; El-Beshlawy, Amal; Fraga, Cristina; Freisens, Selena; Gaemers, Sebastiaan; Hadjiev, Evgueniy; Kishnani, Priya S.; Lukina, Elena; Maison-Blanche, Pierre; Martins, Ana Maria; Pastores, Gregory; Petakov, Milan; Peterschmitt, M. Judith; Rosenbaum, Hanna; Rosenbloom, Barry; Underhill, Lisa H.; Cox, Timothy M.

In: Blood Cells, Molecules, and Diseases, Vol. 77, 01.07.2019, p. 101-102.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Addendum to Letter to the Editor

T2 - Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1

AU - Mistry, Pramod K.

AU - Balwani, Manisha

AU - Baris, Hagit N.

AU - Turkia, Hadhami Ben

AU - Burrow, T. Andrew

AU - Charrow, Joel

AU - Cox, Gerald F.

AU - Danda, Sumita

AU - Dragosky, Marta

AU - Drelichman, Guillermo

AU - El-Beshlawy, Amal

AU - Fraga, Cristina

AU - Freisens, Selena

AU - Gaemers, Sebastiaan

AU - Hadjiev, Evgueniy

AU - Kishnani, Priya S.

AU - Lukina, Elena

AU - Maison-Blanche, Pierre

AU - Martins, Ana Maria

AU - Pastores, Gregory

AU - Petakov, Milan

AU - Peterschmitt, M. Judith

AU - Rosenbaum, Hanna

AU - Rosenbloom, Barry

AU - Underhill, Lisa H.

AU - Cox, Timothy M.

PY - 2019/7/1

Y1 - 2019/7/1

UR - http://www.scopus.com/inward/record.url?scp=85064623158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064623158&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2019.04.003

DO - 10.1016/j.bcmd.2019.04.003

M3 - Letter

VL - 77

SP - 101

EP - 102

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

ER -